OSUR

OraSure Technologies Inc. (OSUR) | Rumor.io

OraSure Technologies

OSUR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,675

Bullish sentiment (50-day avg)0%

Price to earnings ratio19.9

Market capitalization272.4M

Earnings per share-0.69

Dividend yield (TTM)—

Revenue (annual)115M

Net income (annual)-68.7M

Social

What share of all stock conversation is about OSUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 28

Insider purchases of $OSUR stock by CEO, CFO, and 2 Directors totaling ~$600k, marking the first insider buys in almost 2 years.
$OSUR is a small-cap medical device company trading at a 52-week low, with recent insider purchases and no recent sales.
The company's stock has been impacted by disappointing earnings and lack of corporate PR in the past 3 months, but some analysts see potential for a turnaround following the insider purchases.

Generated by AI

Sentiment

Of the messages about OSUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.55% -10.68
Bearish	—	—	—	22.45% +10.68

Bullish· Oct 19

OraSure Technologies, Inc. ($OSUR) has received FDA Emergency Use Authorization for SARS CoV-2, driving a significant price increase.
The company's COVID-19 collection kits and internally-developed antigen and antibody tests are expected to drive additional demand and growth in FY21.
$OSUR has seen a 25% increase in share price since being featured as a top pick, with some traders locking in profits over $17.

Bearish· Aug 6

OraSure Technologies' Q2 revenue was severely impacted by the pandemic, leading to a significant drop in revenue.
The company's poor earnings and misleading outlook have resulted in a stock price decline of over 33%.
The stock's technical analysis suggests it may still have room to drop further, with some analysts predicting a potential price of around $11.50.

Generated by AI

Topics

Of the messages about OSUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	93.52%
Analysts	—	0%	0%	4.17%
Controversies	—	0%	0%	0.46%
Earnings	—	0%	0%	0.46%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.39%

Earnings· Aug 8

OraSure Technologies reported FQ2 earnings of 7c EPS and $43.63M in revenue, beating estimates.
The company's EPS of $0.07 beat the consensus estimate of $0.04, while revenue also exceeded expectations.
OraSure's Q3 earnings guidance was in-line with consensus estimates, with EPS expected to be in-line and revenue above consensus.

Announcements· Nov 2

The U.S. FDA has authorized OraSure Technologies' InteliSwab COVID-19 rapid tests for over-the-counter (OTC) single-use, at-home testing for symptomatic people.
The FDA has also accepted data for the detection of the Delta variant using OraSure's InteliSwab COVID-19 rapid tests.
OraSure Technologies' stock price has increased by up to 9.4% following the FDA's announcement, with the company's InteliSwab COVID-19 rapid tests being amended to require only one test for individuals with symptoms of COVID-19.

Generated by AI

Community

Of the messages about OSUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	4.68%
Newcomers	100%	100%	100%	95.32%

Regulars· Aug 4

OraSure Technologies, Inc. ($OSUR) is expected to report Q3 2023 revenue of $72M-$77M.
The stock has experienced significant gains, rising 21% in early Friday morning trading and reaching within 2 cents of $6.00.
Traders are taking advantage of the momentum, with some selling shares at prices like $5.93 and $5.89.

Newcomers· Feb 15

OraSure Technologies, Inc. (OSUR) reported a Q4 adjusted earnings swing to profitability due to rising sales, but also unveiled job cuts.
The company's FY22 vs FY21 financials show significant increases in total revenue, gross profit, and gross margin, with notable declines in inventories and capital expenditures.
OSUR's Q4 FY 2021 earnings report revealed a net profit margin of -16.35%, with sales and EPS both showing declines, sparking investor interest and surprise.

Generated by AI

On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company’s own guidance range and climbed 9.7% from the prior quarter. But look past the top […]

23d agoYahoo Finance

OraSure Earnings Call: Growth, Setbacks and 2027 Target

Detailed price information for Orasure Tech Inc (OSUR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

OraSure Technologies: Lack Of Near Term Catalysts (NASDAQ:OSUR)

1mo agoSeeking Alpha

OraSure (OSUR) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

OraSure (OSUR) Q2 2026 Earnings Call Transcript

Detailed price information for Orasure Tech Inc (OSUR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

OraSure Technologies, Inc. Q2 2026 Earnings Call Summary

1mo agoYahoo Finance

Also Discussed

Investors talking about OSUR also mention

#	Name	Attention
1	Lakeland Industries, Inc.LAKE	0%0
2	QuidelOrtho CorporationQDEL	0%new
3	HZNP - Horizon Therapeutics Public Limited Company	——
4	FOLD - Amicus Therapeutics, Inc.	——
5	NLTX - Neoleukin Therapeutics, Inc.	——
6	Akebia Therapeutics Inc.AKBA	0.01%+0
7	LUMO - Lumos Pharma, Inc.	——
8	NVRO - Nevro Corp.	——
9	Aspira Women's Health Inc.AWH	0%new
10	Moleculin Biotech, Inc.MBRX	0%0

OraSure Technologies Inc.

Healthcare
Medical Instruments & Supplies

OraSure Technologies Inc. is a medical diagnostics and sample management company focused on point-of-need and home testing solutions. OraSure Technologies Inc. develops, manufactures, markets, and distributes rapid diagnostic tests, oral fluid collection devices, and specimen management products used in infectious disease screening, drug testing, and molecular research. Its portfolio includes products for HIV, hepatitis C, syphilis, and respiratory testing, along with sample collection and stabilization kits that support genomics, microbiome, and other life science workflows. The company serves clinical laboratories, hospitals, public health organizations, physicians, researchers, and other professional markets, playing a role in expanding access to easier specimen collection and diagnostic information.

Website

Location

220 East First Street

Bethlehem, PA, 18015

United States

Social

What share of all stock conversation is about OSUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 28

Insider purchases of $OSUR stock by CEO, CFO, and 2 Directors totaling ~$600k, marking the first insider buys in almost 2 years.
$OSUR is a small-cap medical device company trading at a 52-week low, with recent insider purchases and no recent sales.
The company's stock has been impacted by disappointing earnings and lack of corporate PR in the past 3 months, but some analysts see potential for a turnaround following the insider purchases.

Generated by AI

Sentiment

Of the messages about OSUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.55% -10.68
Bearish	—	—	—	22.45% +10.68

Bullish· Oct 19

OraSure Technologies, Inc. ($OSUR) has received FDA Emergency Use Authorization for SARS CoV-2, driving a significant price increase.
The company's COVID-19 collection kits and internally-developed antigen and antibody tests are expected to drive additional demand and growth in FY21.
$OSUR has seen a 25% increase in share price since being featured as a top pick, with some traders locking in profits over $17.

Bearish· Aug 6

OraSure Technologies' Q2 revenue was severely impacted by the pandemic, leading to a significant drop in revenue.
The company's poor earnings and misleading outlook have resulted in a stock price decline of over 33%.
The stock's technical analysis suggests it may still have room to drop further, with some analysts predicting a potential price of around $11.50.

Generated by AI

Topics

Of the messages about OSUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	93.52%
Analysts	—	0%	0%	4.17%
Controversies	—	0%	0%	0.46%
Earnings	—	0%	0%	0.46%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.39%

Earnings· Aug 8

OraSure Technologies reported FQ2 earnings of 7c EPS and $43.63M in revenue, beating estimates.
The company's EPS of $0.07 beat the consensus estimate of $0.04, while revenue also exceeded expectations.
OraSure's Q3 earnings guidance was in-line with consensus estimates, with EPS expected to be in-line and revenue above consensus.

Announcements· Nov 2

The U.S. FDA has authorized OraSure Technologies' InteliSwab COVID-19 rapid tests for over-the-counter (OTC) single-use, at-home testing for symptomatic people.
The FDA has also accepted data for the detection of the Delta variant using OraSure's InteliSwab COVID-19 rapid tests.
OraSure Technologies' stock price has increased by up to 9.4% following the FDA's announcement, with the company's InteliSwab COVID-19 rapid tests being amended to require only one test for individuals with symptoms of COVID-19.

Generated by AI

Community

Of the messages about OSUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	4.68%
Newcomers	100%	100%	100%	95.32%

Regulars· Aug 4

OraSure Technologies, Inc. ($OSUR) is expected to report Q3 2023 revenue of $72M-$77M.
The stock has experienced significant gains, rising 21% in early Friday morning trading and reaching within 2 cents of $6.00.
Traders are taking advantage of the momentum, with some selling shares at prices like $5.93 and $5.89.

Newcomers· Feb 15

OraSure Technologies, Inc. (OSUR) reported a Q4 adjusted earnings swing to profitability due to rising sales, but also unveiled job cuts.
The company's FY22 vs FY21 financials show significant increases in total revenue, gross profit, and gross margin, with notable declines in inventories and capital expenditures.
OSUR's Q4 FY 2021 earnings report revealed a net profit margin of -16.35%, with sales and EPS both showing declines, sparking investor interest and surprise.

Generated by AI

OraSure Technologies

Social

Feb 28

Bullish· Oct 19

Bearish· Aug 6

Earnings· Aug 8

Announcements· Nov 2

Regulars· Aug 4

Newcomers· Feb 15

OraSure (OSUR) Returns To Profit, But Growth Remains Elusive

OraSure Earnings Call: Growth, Setbacks and 2027 Target

OraSure Technologies: Lack Of Near Term Catalysts (NASDAQ:OSUR)

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies, Inc. Q2 2026 Earnings Call Summary

Also Discussed

OraSure Technologies Inc.

Company Information

Location

OraSure (OSUR) Returns To Profit, But Growth Remains Elusive

OraSure Earnings Call: Growth, Setbacks and 2027 Target

OraSure Technologies: Lack Of Near Term Catalysts (NASDAQ:OSUR)

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies, Inc. Q2 2026 Earnings Call Summary

Also Discussed

Social

Feb 28

Bullish· Oct 19

Bearish· Aug 6

Earnings· Aug 8

Announcements· Nov 2

Regulars· Aug 4

Newcomers· Feb 15